Another randomized controlled trial conducted in 60 adolescents with T1D and non-alcoholic steatohepatitis (NASH) found that 6-month administration of vildagliptin (administered at a daily dose of 50 mg) as an add-on to insulin therapy improved glycemic control and dyslipidemia, decreased matrix metalloproteinase-14 (MMP-14) levels, and reduced liver stiffness and carotid intima-media thickness (CIMT) [135]. Here, MMP14 is linked to metabolic dysfunction-associated steatohepatitis.